cancer
chemotherapi
use
drug
prevent
growth
cancer
cell
kill
cancer
cell
human
bodi
gener
chemotherapi
appli
three
primari
purpos
adjuv
therapi
order
prevent
cancer
cell
reemerg
follow
initi
surgeri
radiat
neoadjuv
therapi
shrink
tumour
size
easier
remov
surgeri
treatment
metastat
diseas
reduc
number
cancer
cell
kill
cell
spread
part
bodi
primari
cancer
locat
lymph
node
arm
patient
breast
cancer
gener
chemotherapeut
drug
use
treat
breast
cancer
includ
follow
anthracyclin
doxorubicin
adriamycin
epirubicin
ellenc
taxan
paclitaxel
taxol
docetaxel
taxoter
cyclophosphamid
cytoxan
capecitabin
xeloda
vinorelbin
navelbin
gemcitabin
gemzar
trastuzumab
herceptin
antihormon
drug
well
breast
cancer
drug
target
human
epiderm
growth
factor
breast
cancer
chemotherapi
commonli
administ
oral
intraven
inject
daili
adjuv
neoadjuv
set
chemotherapeut
drug
usual
given
combin
two
drug
sinc
singledrug
chemotherapi
less
effect
howev
toxic
combin
chemotherapi
also
greater
treatment
programm
plan
appropri
inappropri
combin
chemotherapi
may
abl
treat
reduc
spread
breast
cancer
may
continu
destroy
divid
cell
affect
surround
healthi
tissu
inde
major
current
chemotherapi
caus
pain
advers
effect
patient
includ
nausea
vomit
loss
appetit
fatigu
mouth
sore
hair
loss
weight
gain
prematur
menopaus
reduc
resist
infect
increas
bleed
therefor
import
seek
effect
treatment
strategi
combin
therapi
breast
cancer
use
novel
compoundssubst
natur
product
frequent
reduc
toxic
comparison
tradit
chemotherapi
naturallyoccur
anticanc
product
may
reduc
pain
prevent
spread
cancer
cell
part
bodi
convent
drug
screen
process
divid
two
main
stage
discoveri
develop
discoveri
stage
divid
earli
discoveri
lead
identif
lead
optim
select
candid
proceed
preclin
screen
stage
fig
earli
discoveri
research
phase
screen
process
thousand
potenti
compound
extract
synthesis
variou
resourc
annual
hope
certain
compound
may
possess
promis
therapeut
effect
accord
pharmaceut
research
manufactur
america
one
drug
select
everi
test
compound
end
screen
process
entir
process
cost
billion
euro
requir
year
complet
therefor
initi
vitro
step
screen
process
particularli
import
increas
speed
earli
highthroughput
process
identifi
specif
desir
effect
compound
crucial
current
studi
aim
develop
novel
screen
assay
acceler
identif
specif
compound
prior
anim
studi
preclin
stage
popular
vitro
strategi
identifi
preliminari
growth
inhibitori
effect
potenti
agent
frequent
involv
use
cellbas
prolifer
assay
includ
secondari
metabolit
detect
condit
medium
use
tetrazolium
salt
mtt
assay
cell
membran
damag
detect
assess
dehydrogenas
releas
damag
cell
dna
fragment
detect
via
situ
assay
assay
use
cell
stain
flow
cytometri
conduct
assay
requir
costli
laboratori
facil
cell
cultur
expertis
cultur
sensit
impur
test
agent
may
caus
contamin
unless
crude
extract
use
dissolv
antimicrobi
solvent
dimethyl
sulfoxid
furthermor
assay
reli
slowgrow
cell
line
multipl
passag
may
also
chang
genotyp
phenotyp
cell
thu
costeffect
approach
requir
overcom
limit
subject
unidentifi
compound
cellbas
screen
earli
screen
process
costli
present
studi
aim
develop
yeastbas
screen
assay
use
pichia
pastori
transform
plasmid
express
dna
topoisomeras
topoi
name
dna
topoisomeras
involv
cell
prolifer
thu
overexpress
enzym
yeast
enhanc
prolifer
mimick
cancer
cell
use
yeastbas
assay
versatil
allow
screen
larger
number
compound
without
need
cell
cultur
facil
expertis
produc
similar
find
compar
cellbas
assay
therefor
assay
result
faster
preliminari
screen
process
candid
compound
exhibit
posit
effect
earli
discoveri
stage
proceed
next
step
drug
discoveri
process
pichia
pastori
strain
clone
carri
topoi
plasmid
gener
previou
studi
refer
clone
use
develop
yeastbas
screen
assay
present
studi
assay
design
follow
characterist
easi
oper
special
skill
requir
ii
specif
equip
requir
perform
simpl
laboratori
setup
instanc
use
shaker
flask
system
iii
yeast
cell
densiti
main
compon
assay
therefor
addit
detect
kit
enzym
reagent
need
chemic
medium
reagent
maintain
yeast
cell
iv
short
amount
time
requir
complet
full
assay
week
assay
perform
room
temperatur
least
laboratori
equip
aircondition
v
produc
result
compar
cellbas
screen
assay
yeast
cultur
stock
construct
store
glycerol
previous
describ
retriev
enrich
use
ml
buffer
glycerolcomplex
medium
bmgi
univers
bottl
transform
yeast
strain
incub
overnight
incub
shaker
rpm
subsequ
overnight
cultur
transfer
ml
conic
flask
contain
ml
fresh
bmgi
cultur
incub
shaker
anoth
h
agit
rpm
exponenti
growth
phase
reach
growth
yeast
cell
induc
use
vv
methanol
h
incub
cultur
medium
glutam
lglutam
acid
puriti
sigmaaldrich
merck
kgaa
darmstadt
germani
serv
growth
agonist
ad
cell
incub
h
small
volum
sampl
withdrawn
treat
cultur
everi
h
cell
densiti
measur
yeast
cell
densiti
expect
enhanc
condit
option
step
involv
replenish
volum
medium
contain
drug
solut
order
maintain
origin
cultur
volum
throughout
assay
methanol
ad
everi
h
altern
camptothecin
puriti
sigmaaldrich
merck
kgaa
serv
growth
antagonist
ad
cultur
instead
glutam
similar
glutamatetr
cell
sampl
withdrawn
yeast
cell
cultur
treat
camptothecin
everi
h
cell
densiti
measur
cell
densiti
expect
inhibit
cultur
condit
cell
densiti
cultur
turbid
collect
sampl
assess
optic
densiti
nm
everi
h
h
use
spectrophotomet
turbid
level
sampl
record
valu
sampl
compar
valu
background
control
next
growth
profil
yeast
timepoint
plot
densiti
unit
yeast
cultur
expect
grow
continu
reduc
follow
treatment
glutam
camptothecin
respect
h
compar
densiti
background
control
rel
measur
h
cultiv
normal
yeast
yeast
transform
plasmid
without
insert
gene
use
control
subsequ
overal
respons
yeast
cultur
treat
camptothecin
compar
perform
drug
cellbas
mtt
assay
expect
mimic
cancer
cell
mtt
assay
conduct
examin
effect
camptothecin
variou
human
cell
line
compar
effect
yeast
cell
cell
line
use
assay
includ
highli
metastat
breast
cancer
cell
weakli
metastat
oral
cancer
breast
cancer
cell
bone
marrowderiv
mesenchym
stem
cell
normal
breast
cell
cell
line
use
present
studi
previous
purchas
american
type
cultur
collect
manassa
va
usa
cultur
respect
growth
medium
laboratori
cancer
cell
maintain
high
glucos
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
streptomycinpenicillin
wherea
noncancer
cell
maintain
medium
supplement
mgml
epiderm
growth
factor
mgml
hydrocortison
mgml
insulin
fb
penicillinstreptomycin
aforement
cultur
reagent
purchas
gibco
thermo
fisher
scientif
inc
waltham
usa
briefli
cellsml
cell
line
seed
plate
routin
cultur
humidifi
incub
h
cell
reach
confluenc
subsequ
cell
treat
increas
concentr
camptothecin
solut
h
end
incub
period
mtt
reagent
mgml
sigmaaldrich
merck
kgaa
ad
well
reaction
incub
h
solut
care
remov
without
disturb
formazan
crystal
form
well
subsequ
acidifi
isopropanol
ad
well
agit
homogen
colour
develop
follow
colour
develop
intens
colour
plate
measur
nm
use
elisa
plate
reader
dose
respons
curv
gener
cell
viabil
plot
logarithm
scale
log
concentr
drug
use
respons
camptothecin
cellbas
yeastbas
assay
compar
graph
gener
statist
analysi
data
perform
use
oneway
analysi
varianc
via
friedman
test
graphpad
prism
softwar
version
window
graphpad
softwar
inc
la
jolla
ca
usa
subsequ
initi
measurementanalysi
experi
repeat
twice
cell
densiti
measur
total
three
time
cell
inhibitori
effect
analysi
total
confirm
consist
repeat
reproduc
result
valu
express
mean
standard
deviat
p
consid
indic
statist
signific
differ
cell
densiti
yeast
strain
gradual
increas
h
cultiv
unit
p
reach
peak
valu
unit
h
p
fig
follow
peak
cell
densiti
reduc
h
cultiv
onward
yeast
growth
reach
lowest
level
unit
h
similar
growth
profil
observ
transform
empti
plasmid
maintain
cultur
without
treatment
fig
cell
densiti
significantli
increas
h
unit
p
reach
optimum
growth
level
unit
h
p
reduc
unit
h
p
cell
densiti
reach
lowest
level
unit
h
p
lower
minim
level
observ
normal
phenomenon
may
due
transform
plasmid
vector
yeast
caus
cell
fragil
contrast
differ
growth
curv
observ
transform
plasmid
carri
topoi
gene
significantli
higher
cell
densiti
observ
h
unit
p
h
unit
p
h
unit
p
cultiv
yeast
growth
remain
high
later
time
point
fig
although
growth
yeast
slightli
reduc
h
onward
cell
reach
lowest
level
growth
observ
yeast
strain
cell
densiti
h
unit
p
h
unit
p
remain
significantli
higher
compar
h
group
indic
transform
topoi
gene
enhanc
growth
yeast
shown
fig
treat
glutam
exhibit
significantli
higher
cell
densiti
unit
h
compar
h
cell
densiti
glutamatetr
reach
optimum
level
unit
h
p
maintain
approxim
level
h
cultiv
cell
densiti
unit
p
unit
p
unit
p
h
cultiv
respect
similarli
glutamatetr
growth
yeast
reach
unit
h
p
optimum
level
unit
h
cultiv
p
cell
continu
grew
level
h
cultiv
fig
cell
densiti
unit
p
unit
p
unit
p
h
respect
howev
growth
profil
glutamatetr
observ
expect
recombin
yeast
grew
steadili
earli
cultiv
cell
densiti
unit
p
unit
p
unit
p
h
cultiv
respect
fig
cell
densiti
reach
unit
h
cultiv
similar
optimum
level
unit
observ
h
cultiv
p
phenomenon
indic
use
glutam
topoi
cultur
may
creat
competit
among
compon
growth
cell
slightli
stunt
result
delay
reach
optimum
growth
level
growth
three
yeast
type
clearli
respond
glutam
treatment
cultur
indic
recombin
yeast
may
use
estim
effect
potenti
agent
cancer
treatment
treat
camptothecin
h
exhibit
similar
optimum
level
cell
densiti
glutamatetr
h
cultiv
treat
yeast
still
capabl
maintain
cell
densiti
unit
h
cultiv
p
optimum
level
unit
h
cultiv
p
fig
howev
cell
densiti
subsequ
reduc
unit
growth
gradual
maintain
level
h
camptothecintr
similar
growth
profil
observ
cell
densiti
unit
h
p
peak
level
unit
reach
h
p
fig
growth
yeast
reduc
unit
growth
continu
level
h
cultiv
notabl
camptothecin
induc
inhibitori
effect
demonstr
two
yeast
clone
despit
markedli
lower
cell
densiti
yeast
express
camptothecin
target
topoi
h
compar
recombin
yeast
grew
steadili
cell
densiti
unit
throughout
experi
growth
recombin
yeast
inhibit
camptothecin
treatment
statist
signific
chang
observ
fig
camptothecin
treatment
expect
reduc
yeast
cell
densiti
howev
treatment
entir
inhibit
yeast
growth
indic
aggress
may
compar
highli
metastat
human
cancer
cell
treatment
cell
camptothecin
h
produc
typic
doserespons
curv
fig
similarli
typic
doserespons
observ
cell
follow
treatment
camptothecin
h
camptothecin
produc
logist
doserespons
cell
treatment
perform
h
maxim
respons
fig
maxim
doserespons
camptothecin
cell
observ
improv
treatment
h
maxim
respons
h
maxim
respons
h
maxim
respons
fig
gener
chemosensit
camptothecin
better
cell
comparison
cell
although
similar
dose
respons
observ
maxim
respons
maxim
respons
cell
treat
h
shown
fig
camptothecin
produc
typic
doserespons
cell
treat
h
maxim
respons
howev
effect
sustain
h
treatment
semiparabol
growth
profil
gener
growth
curv
convey
resist
organ
particular
drug
treatment
produc
treatment
perform
h
phenomenon
indic
reduc
growth
h
treatment
onward
may
due
byproduct
accumul
cultur
preliminari
find
indic
consider
similar
initi
respons
cell
recombin
yeast
camptothecin
treatment
present
studi
demonstr
common
growth
profil
observ
untreat
wherea
growth
enhanc
observ
transform
topoi
gene
via
plasmid
name
glutam
enhanc
growth
howev
combin
topoi
express
cultur
treatment
multipli
growth
effect
contrast
camptothecin
reduc
cell
growth
h
cultiv
show
effect
cell
densiti
notabl
lower
earli
treatment
yeast
express
topoi
camptothecin
compar
yeast
strain
howev
cell
growth
remain
stabl
throughout
experi
phenomenon
indic
difficult
reduc
growth
transform
similar
phenomenon
observ
highli
metastat
breast
cancer
cell
treat
camptothecin
develop
laboratori
newli
simplifi
prototyp
potenti
use
antigrowth
compound
screen
cell
densiti
growth
inhibit
use
paramet
measur
effect
compound
yeast
techniqu
may
use
screen
potenti
growth
inhibitor
futur
similar
strategi
use
enabl
highthroughput
screen
novel
pharmacolog
modul
k
channel
previou
studi
assay
develop
base
growth
yeast
function
express
mammalian
channel
anoth
studi
less
demand
phenotyp
yeastbas
assay
micropl
establish
use
methylaminesensit
yeast
strain
methylamineperm
aquaporin
express
rescu
prolifer
select
plate
wherebi
specif
inhibit
aquaporin
directli
correl
reduc
cell
prolifer
engineeredfiss
yeast
strain
also
use
highthroughput
screen
phosphodiesteras
pde
inhibitor
possess
druglik
characterist
period
assess
growth
behaviour
yeast
determin
activ
heterolog
cyclic
nucleotid
pde
system
could
use
screen
cdna
librari
biolog
regul
target
pde
identifi
whether
differ
pde
protein
complex
exhibit
distinct
pattern
inhibitor
sensit
specif
highthroughput
yeastbas
growth
assay
also
use
screen
potenti
inhibitor
howev
identifi
compound
inhibit
requir
biolog
role
enzym
poorli
understood
addit
robust
yeastbas
growth
assay
potenti
applic
numer
equilibr
nucleosid
transport
ent
develop
order
identifi
inhibitor
malari
parasit
plasmodium
falciparum
inhibitor
detect
base
abil
rescu
growth
yeast
presenc
cytotox
substrat
data
support
hypothesi
block
purin
transport
may
novel
compel
approach
antimalari
drug
develop
contrast
express
xenopu
cyclin
induc
yeastbas
growth
interfer
assay
order
elev
activ
cell
divis
cycl
kinas
yeast
hyperactiv
kinas
yeast
result
growth
arrest
thu
compound
rescu
cyclin
growth
arrest
may
potenti
novel
antitumour
drug
candid
act
cyclindepend
kinasemedi
cell
cycl
regul
pathway
assess
growth
behaviour
enzym
target
cell
need
purifi
specif
time
point
screen
purpos
strategi
provid
simpl
solut
meet
gener
laboratori
need
without
requir
specif
facil
equip
carri
preliminari
screen
approach
potenti
growth
inhibitor
inde
addit
detect
kit
enzym
reagent
requir
chemic
medium
reagent
requir
maintain
recombin
yeast
assay
ideal
use
screen
synthet
compound
plant
extract
nanoparticl
small
molecul
chemic
compound
extract
natur
product
includ
flavonoid
agent
produc
posit
effect
yeastbas
approach
proceed
subsequ
step
requir
costli
gelbas
cellbas
assay
best
knowledg
major
cellbas
assay
typic
requir
day
accomplish
wherea
yeastbas
assay
requir
day
fig
reduc
durat
screen
process
may
save
month
work
year
requir
develop
drug
origin
test
compound
therefor
yeastbas
strategi
save
time
money
resourc
make
screen
procedur
practic
versatil
competit
market
well
afford
research
lowresourc
laboratori
yeastbas
strategi
describ
present
studi
develop
construct
pichia
multipl
copi
number
topoi
express
purif
target
enzym
yeast
found
better
pichia
strain
accommod
exogen
recombin
topoi
express
enzym
activ
ul
crude
cultur
obtain
recombin
yeast
howev
abl
stabli
express
enzym
cultur
supernat
room
temperatur
prototyp
develop
base
present
origin
research
provid
innov
novelti
screen
process
within
medic
biotechnolog
sector
yeast
express
higher
level
topoi
exhibit
similar
highli
metastat
human
cancer
cell
exhibit
similarli
robust
cell
growth
determin
respect
growth
inhibit
assay
use
costeffect
yeastbas
assay
conduct
highthroughput
screen
targetspecif
growth
inhibitor
acceler
identif
potenti
compound
novel
antitumour
drug
reduc
toxic
compar
current
chemotherapi
requir
may
improv
treatment
patient
breast
cancer
similar
strategi
previous
conduct
use
simplifi
yeastbas
screen
approach
search
activ
follow
evalu
activ
select
compound
two
human
tumour
cell
line
includ
acut
promyelocyt
leukaemia
breast
adenocarcinoma
cell
proof
principl
strategi
demonstr
effect
yeast
assay
discoveri
caspas
activ
may
pave
way
new
class
caspas
activ
improv
anticanc
properti
similar
yeastbas
assay
use
platform
screen
identifi
variou
type
compound
instanc
rapid
twostep
yeastbas
assay
develop
screen
antiprion
drug
assay
use
identifi
compound
effect
bud
yeast
prion
respons
psi
phenotyp
effici
highthroughput
screen
approach
identif
novel
prion
inhibitor
addit
robust
highthroughput
yeastbas
assay
determin
potenti
genotox
mutagen
drug
candid
earli
discoveri
phase
drug
develop
creat
replac
wide
use
ame
salmonella
test
readili
adapt
highthroughput
screen
assess
mutagen
genotox
yeastbas
system
assay
dna
repair
abl
detect
genotox
incorpor
metabol
activ
assay
effici
requir
littl
time
small
amount
compound
adapt
highthroughput
platform
yield
data
accur
reproduc
detect
dna
damag
base
metabol
activ
furthermor
use
genet
tractabl
model
yeast
vehicl
targetbas
highthroughput
screen
overcom
numer
limit
vitro
biochem
phenotyp
assay
platform
drug
discoveri
allow
identif
ontarget
compound
function
within
eukaryot
cellular
context
yeastbas
assay
monitor
gardepend
inhibit
translat
also
establish
identifi
doxorubicin
compound
specif
interfer
gar
effect
translat
yeast
approach
thu
valid
effect
highthroughput
screen
assay
identif
drug
interfer
epsteinbarr
viru
ebv
immun
evas
may
candid
treat
ebvassoci
diseas
includ
cancer
anoth
yeastbas
system
identifi
screen
inhibitor
coronaviru
mtase
develop
use
microtit
plate
order
examin
mtase
inhibitor
previous
identifi
use
vitro
biochem
assay
sinefungin
effect
suppress
result
valid
applic
yeastbas
assay
system
inhibitor
screen
also
demonstr
differ
vitro
cellbas
biochem
assay
wherebi
potent
inhibitor
reduc
activ
coronaviru
base
human
identifi
addit
coronaviru
develop
fulli
autom
antiparasit
drugscreen
yeast
system
report
allow
multipl
parasit
target
assess
simultan
due
express
differ
fluoresc
protein
yeast
strain
compound
specif
target
parasit
enzym
select
assay
rather
host
counterpart
thu
enabl
earli
elimin
compound
carri
potenti
side
effect
system
compound
discrimin
host
parasit
enzym
exclud
includ
strain
express
human
target
multiplex
screen
advantag
type
assay
includ
use
known
target
lack
requir
vitro
cultur
parasit
rapid
yeastbas
assay
also
establish
screen
activ
drug
human
inherit
mitochondri
diseas
affect
atp
synthas
particular
ataxia
neuropathi
retin
pigmentosa
syndrom
uniqu
abil
yeast
surviv
without
product
atp
oxid
phosphoryl
use
identifi
chlorhexidin
screen
chemic
librari
oleat
candid
approach
furthermor
highthroughput
yeastbas
screen
bioassay
also
use
detect
select
oestrogen
receptor
modul
select
androgen
receptor
ar
modul
screen
commerci
chemic
librari
identifi
inhibitor
robustli
identifi
new
lead
compound
target
specif
enzym
detect
toxic
human
ca
isozym
ii
hcaii
inhibitor
achiev
use
multidrugsensit
deriv
strain
express
low
level
hcaii
final
use
yeast
present
advantag
relev
surrog
model
eukaryot
cell
process
miniaturis
autom
best
knowledg
major
screen
assay
develop
use
saccharomyc
cerevisia
instanc
miniaturis
shortterm
vivo
genotox
screen
assay
base
genet
modifi
cerevisia
perform
explor
chronic
cytotox
genotox
effect
compound
eukaryot
organ
anoth
exampl
effici
reliabl
yeastbas
detect
system
creat
evalu
androgen
activ
endocrin
disruptor
pulp
paper
mill
effluent
system
use
cerevisia
transform
gene
report
express
driven
human
ar
respons
element
order
identifi
compound
alter
report
gene
induct
testosteron
find
assay
suggest
pulp
paper
mill
effluent
rich
androgen
chemic
detect
system
could
applic
primari
screen
method
inhibitorsactiv
ar
function
cerevisia
also
use
screen
polymorph
human
gene
heat
shock
protein
essenti
cell
prolifer
bud
yeast
speed
low
cost
make
yeastbas
assay
use
tool
identifi
human
polymorph
protein
addit
sensit
fast
userfriendli
progesteron
receptor
pr
transactiv
assay
establish
use
recombin
cerevisia
modifi
express
green
fluoresc
protein
driven
human
pr
progesteron
respons
element
stimul
cell
increas
concentr
progesteron
result
signific
elev
fluoresc
activ
yeastbas
bioassay
provid
robust
rapid
method
highthroughput
screen
anti
progest
compound
variou
sourc
anoth
cerevisia
model
system
also
use
investig
regul
human
osmot
stress
condit
rescu
growth
strain
carri
doubl
tripl
mitogenactiv
protein
kinas
delet
high
osmolar
glycerol
result
previou
studi
demonstr
potenti
use
cerevisia
investig
identifi
function
interactor
uncov
new
cancerassoci
gene
therapeut
potenti
brief
live
yeast
cellbas
assay
rapid
inexpens
sensit
amen
highthroughput
method
use
varieti
applic
includ
isol
novel
gene
direct
evolut
genespecif
drug
screen
facilit
variou
approach
numer
research
area
current
studi
pichia
use
host
express
topoi
rather
saccharomyc
due
simplic
techniqu
requir
molecular
genet
manipul
similar
saccharomyc
furthermor
abil
pichia
produc
foreign
protein
higher
level
intracellularli
extracellularli
abil
perform
eukaryot
posttransl
modif
make
yeast
strain
suitabl
produc
protein
human
applic
also
offer
competit
lowcost
strategi
potenti
growth
inhibitor
screen
may
access
lowresourc
laboratori
set
still
enabl
highthroughput
screen
process
topoi
focu
present
studi
enzym
gener
target
screen
potenti
growth
inhibitor
use
effect
compound
combin
use
breast
cancer
chemotherapi
drug
sinc
variou
anticanc
drug
includ
camptothecin
topoi
inhibitor
conclus
current
studi
develop
preliminari
form
yeastbas
system
costeffect
fast
easi
oper
effici
compound
screen
system
expect
overcom
certain
limit
cellbas
prolifer
assay
maintain
similar
screen
function
although
yeastbas
bioassay
establish
power
approach
identifi
potenti
therapeut
compound
creat
robust
model
amen
highthroughput
screen
remain
challeng
therefor
studi
focu
area
ensur
function
assay
implement
effect
futur
